Blueprint Medicines Corp
BPMC evidence brief
What we can confirm
- BioSniper Score:
- 8.6 / 10
- Lead Asset:
- avapritinib (Phase 4)
What it means
What to watch
Prepared research question
What matters most for BPMC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 4 pipeline candidates · 14 clinical trials · 2 FDA decisions for Blueprint Medicines Corp.
Run Blueprint Medicines Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Blueprint Medicines Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is Blueprint Medicines Corp's lead drug candidate?
Blueprint Medicines Corp's most advanced tracked candidate is avapritinib (Phase 4) for Solid Tumor, Unspecified, Child; Indolent Systemic Mastocytosis; Mastocytosis, Systemic.
Who is the CEO of Blueprint Medicines Corp?
Blueprint Medicines is the chief executive officer of Blueprint Medicines Corp (BPMC).
What therapeutic areas does Blueprint Medicines Corp focus on?
Blueprint Medicines Corp develops therapies across Oncology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.